Different physicians tend to learn in different ways, but most retain and use needed information when it is presented in a clinically relevant manner and when the reasoning behind decisions on clinical care is explained and demonstrated. Clear identification of the goals of treatment for any patient at any stage of management greatly facilitates optimal management decisions.
Consultant: I agree that chemotherapy is indicated. Evidence suggests that chemotherapy can prolong survival in intermediate and advanced stages of CLL. Whether purine analogues are superior to alkylating agents remains unproven, and whether cross resistance occurs when fludarabine follows cladribine failure is controversial. The limited data indicate that cladribine is not beneficial when used as a salvage treatment after failing a trial of fludarabine.
After the first cycle of cladribine, the patient's hemoglobin level dropped to 7.4 g/dL, and a transfusion with two units of packed red blood cells was administered. Direct and indirect Coombs tests were negative, and there was no evidence of blood loss. After two courses of chemotherapy, lymph nodes had decreased somewhat in size, and the spleen decreased from 6 cm below the left costal margin to 4 cm. His WBC count decreased to 20,000/ mm 3 , his hemoglobin level was 9.3 g/dL, and his platelet count was 198,000/mm 3 . Chemotherapy was continued and trimethoprim-sulfametoxazole was administered as prophylaxis against Pneumocystis carinii pneumonia (PCP) infection.
Consultant: The patient seems to be responding to chemotherapy, although the drop in hemoglobin level after one course of chemotherapy is unusual. The drop does not appear to be due to hemolysis of red blood cells or bleeding. Purine analogues can cause profound CD4 lymphocyte depletion. Many physicians use trimethoprimsulfametoxazole for PCP prophylaxis analogous to prophylaxis in patients with AIDS. However, there are few empiric data to support this practice in cladribine/fludarabine treatment of CLL. I believe that continuing treatment with cladribine is reasonable as long as the patient is responding and there is no significant toxicity.
The patient received another two courses of cladribine. His WBC count further decreased to 3,700/mm 3 with 35% lymphocytes, 60% neutrophils, 2% monocytes, and 3% eosinophils. His hemoglobin level remained stable at 9.8 g/dL, and his platelet count was 148,000/mm 3 . However, he developed bulky cervical, axillary, and inguinal lymphadenopathy. Two weeks after the fourth course of cladribine, he was admitted to the hospital with neutropenic sepsis. His WBC count was 1,000/mm 3 with 7% neutrophils, with a hemoglobin level of 10 g/dL and a platelet count of 115,000/mm 3 . He was treated successfully with broad-spectrum antibiotics and discharged with a WBC count of 3,200/mm 3 . A bone marrow biopsy revealed almost 100% infiltration with leukemic cells. The patient was treated with three courses of fludarabine. The patient had a partial response but experienced severe neutropenia. He underwent a MUD bone marrow transplant after treatment with high-dose cyclophosphamide and total body irradiation. He tolerated the transplant well except for mild graft-vs -host disease (GVHD) involving the skin, which was successfully treated with glucocorticoids. Two months after transplant, a bone marrow biopsy and flow cytometry showed no evidence of CLL. Restrictionfragment polymorphism analysis was consistent with the engraftment. Three months after transplant, he was doing well. His WBC count was 3,700/mm 3 with 60% neutrophils and 30% lymphocytes, his hemoglobin level was 8 g/dL, and his platelet count 20,000/mm 3 . He continued to receive cyclosporine and corticosteroids for GVHD prophylaxis, and penicillin, trimethoprim-sulfametoxazole, fluconazole, acyclovir, and weekly gamma globulins for infection prophylaxis. He still required occasional hemoglobin and platelet transfusions. Eight months after transplant, the patient developed fever associated with shortness of breath and coughing. A chest radiograph showed a cavitary lesion in the right upper lobe consistent with of an aspergillus infection. Despite treatment with amphotericin B, his condition continued to deteriorate, and the patient died 14 days after treatment with amphotericin B.
Consultant

Discussion
This case illustrates several aspects of clinical reasoning often used by physicians in managing malignant diseases. As in other areas in medicine, the initial approach is to establish a diagnosis, which lays the groundwork for determining prognosis or management goals. 1 The Table sumarizes salient features of decision making presented in this case.
Diagnosis is frequently less of a cognitive challenge in oncology than in other aspects of patient care. Our discussant rapidly arrived at the diagnosis of CLL. Although many factors can lead to an increase in lymphocyte count, few induce slowly progressive lymphocytosis in an asymptomatic patient. When CLL is suspected, the diagnosis should be confirmed with bone marrow studies and/or immunotyping to document a monoclonal expansion of lymphocytes. 2 Confirmation of the diagnosis is facilitated by detection of a unique combination of B-cell differentiation antigens such as CD19, CD20, CD21, and CD23 with a normal T-cell antigen, CD5, on the CLL cells. 2, 3 As the consultant pointed out, the presence of these antigens, detected via antigen-specific monoclonal antibodies using flow cytometry, immunohistochemical reactions, or fluorescence microscopy, is diagnostic of CLL. 3, 4 The major thrust of the illustrated case is reasoning by identification of management goals. To define the goals, physicians attempt to predict the course of the disease in the individual patient by using statistical rules (prognostic factors) derived from groups of patients. They also use reasoning by extrapolation of data from one clinical setting to another. To determine the most appropriate treatment option, they weigh the available data about benefits and risks in a comparison among competing therapeutic strategies. 5 Goal-oriented management in oncology typically begins with the question, "Can disease in this patient be cured?" If the answer is yes, the next questions are, "What is the price of cure? Do the benefits of treatment exceed the risks?" 5 For example, chronic myelogenous leukemia can be cured in a 70-year-old patient using BMT with the risk of a high short-term mortality. 6 In this situation, an appropriate approach may be a conservative, less risky treatment that cannot cure the disease but consistently results in several years of survival.
6
Reasoning Principles Illustrated in This Case
Identification of goals of the treatment (cure vs prolongation of survival vs palliation) represents one of the fundamental reasoning processes in clinical oncology.
To achieve a given therapeutic goal, physicians should compare benefits and risks of available treatment options. Physicians should be aware of possible differences in decision making based on the aggregate data from a group of patients and those in caring for an individual patient.
If
In the present case, both the physician-in-charge and our discussant concluded at the first encounter that CLL cannot be cured. The treatment of early-stage CLL does not prolong survival and can result in shortened survival due to an increased incidence of secondary malignancies associated with chemotherapy. 8 Furthermore, survival in patients with early clinical stage can be long (10 years or more), 2 and some of these patients have a median survival duration equal to that of the control population. 3, [9] [10] [11] [12] These patients are said to have "smoldering" CLL. [10] [11] [12] [13] The critical problem for the physician is to distinguish these patients from those in whom disease will behave more aggressively. Both the physician-in-charge and our discussant used prognostic factors to estimate the likely course of the disease. 11, 12 Several prognostic factors have been proposed to describe "smoldering" CLL and to identify those patients who do not need immediate treatment. 11, 12 "Smoldering" CLL is characterized by normal hemoglobin and platelet values, fewer than two areas of lymph node enlargement, peripheral blood lymphocytes of less than 30,000/mm 3 , lymphocyte doubling time greater than 12 months, and nondiffuse bone marrow involvement. [10] [11] [12] Our patient had only one adverse factor -diffuse bone marrow infiltration.
However, all other prognostic factors were favorable. The physician-in-charge and our discussant therefore believed that the patient would do well and indicated no therapeutic intervention. In doing so, they relied on the use of prognostic factors. In addition to the stage of the disease, five other prognostic factors are typically used in CLL: (1) the number of lymphocytes in blood (<50,000 vs >50,000/mm 3 ), (2) doubling time (<12 months vs >12 months), (3) lymphocyte morphology in peripheral blood (<5% prolymphocytes vs >5% prolymphocytes), (4) cytogenetic abnormalities (normal karyotype vs multiple and complex abnormalities), and (5) bone marrow histopathologic pattern (nondiffuse vs diffuse). 14 Our patient was stage 0 and had one of the five unfavorable prognosticators (diffuse bone marrow involvement). No method has been developed to use all prognostic factors in a single score to indicate probability of long-term survival. Instead, physicians and patients must make their best "guess" as to which one of these factors would determine the prognosis. To supplement the lack of accurate prognostic tools, physicians usually resort to a time-honored practice: regular patient follow-up.
Unfortunately, the outcome in this case did not occur as predicted. 15 Within six months of diagnosing "favorable" CLL, the disease had progressed to an advanced stage. The patient's survival was now estimated to be jeopardized, and an intervention could possibly lead to prolonged survival. 3, 4, 16, 17 Once the need for intervention is identified, the next dilemma faced by physicians who care for patients with CLL is choice of therapy. Standard therapy with alkylating agents or multiagent combinations results in prolonged survival but not in cure. 3, 4, 14 Furthermore, true complete remissions with standard chemotherapy 14, 17, 18 are rare, usually not exceeding 10% even by standard hematologic criteria. 3, 19, 20 New purine analogues, however, have much higher remission rates. Some of these agents appear to induce true, durable, complete molecular remissions and thus raise the possibilty of cure. 21, 22 Faced with aggressive disease in a young patient with CLL who has a significantly reduced life expectancy, 2-4 the physician-in-charge in the illustrated case and two other consultants recommended purine analogues as first-line treatment for this patient. They believed that treatment with chlorambucil would be palliative at best and that the treatment with purine analogues might result in long-term remission, if not in cure. However, our discussant was correct to point out that the remissions achieved by purine analogues have not as yet been shown to result in a survival advantage and certainly not in cures. Chlorambucil is still considered standard initial therapy by many physicians. However, in a recent US randomized trial, the complete remission rate for fludarabine was 33% vs 8% for chlorambucil. Whether this will translate into a survival advantage for fludarabine is not clear at this time. 23 The next dilemma for the physician-in-charge was determining which purine analog to recommend. 3, 4, 14 Cladribine and fludarabine have been shown to be equally effective.
However, cladribine is not effective salvage therapy after fludarabine failure, 24 whereas fludarabine has not been shown to be ineffective salvage therapy following cladribine failure. Initial treatment with fludarabine might narrow the future treatment options in the case of a treatment failure. For this reason, cladribine was chosen as the initial therapy. Faced with two uncertain options, physicians frequently choose to avoid regret that commonly occurs when expectations do not meet outcomes. 25, 26 After treatment with cladribine resulted in a poor response and fludarabine led only to tumor reduction rather than complete remission, it was estimated that life expectancy of our patient was dismal. What should be the goal of treatment now?
The physician extrapolated data from other clinical trials despite the absence of CLL studies that high-dose chemotherapy followed by BMT could potentially cure this patient's CLL. But what type of BMT should be recommended? The choice lies between allogeneic BMT (allo-BMT), with a matched related or unrelated donor, and auto-BMT. If a matched related donor were not available, would BMT with MUD be preferred over auto-BMT? Comparison of benefits and risks among competing therapeutic options is the reasoning principle used to select of the final treatment. 5 The main limitation of auto-BMT for CLL is a high relapse rate and questionable curative potential. 27 Allo-BMT can eradicate CLL and can result in a complete clinical and molecular remission. 3, 4, [28] [29] [30] Due to short follow-up, it is unclear whether these remissions will translate into cures. Following allogeneic stem cell transplantation with matched siblings for CLL, the complete remission rate is 80% to 90%. [30] [31] [32] [33] The projected disease-free survival plateaus at approximately 55%. [30] [31] [32] [33] Most such patients undergoing allo-BMT had a chemorefractory disease, similar to our patient. However, the main obstacle for the allo-BMT is a transplantation-related mortality that varies between 10% to 50%; a large series for HLA-identical siblings reported a 47% mortality. 34 No extensive series of MUD transplants in CLL are available, only limited case reports. However, complete hematologic, immunologic, and molecular remissions have been readily achieved and long-term survivors (1 to 4 years) have been reported. 33, 35 The National Marrow Donor Program data show that at least 38 patients with CLL have been transplanted with matched unrelated donors. 36 The transplant-related mortality in MUD transplants for chronic leukemias is approximately 50%. 36, 37 Therefore, evidence-based recommendations are difficult to make in this clinical setting. When data are lacking, how should physicians and their patients proceed?
Faced with a dilemma of a severely compromised life expectancy vs the possibility of cure, 38 the physician-in-charge, two BMT specialists, and the discussant in the above case believed that the potential benefits of BMT justified its risks.
Unfortunately, a matched related donor was not found. Auto-BMT would have been less toxic 27, 34 but would have had less chance at achieving a long-term remission. 27 Faced with the alternatives of auto-BMT, a MUD transplant, or palliative therapy in the setting of rapidly progressive, chemoresistant disease, the clinicians chose the most aggressive approach of a MUD transplant. They felt that a high-risk procedure such as MUD BMT 3,4,39 had a greater potential benefit than either palliative care or auto-BMT. Although the patient's risk of life-threatening complications was exceedingly high with MUD, his prognosis with palliative treatment and auto-BMT were believed to be equally dismal. Thus, the physician-in-charge, two BMT specialists, and the discussant recommended MUD, the therapeutic approach with the potential for a long-term benefit. They recommended this treatment without firm data on benefits and risks of MUD BMT in CLL, assuming analogy to the treatment of other chronic leukemias, such as chronic myelogenous leukemia. 6, 37 Using the principle of analogy to extrapolate data from one setting to another is not unique to oncology and is deeply woven into the fabric of medical thought. 40, 41 Despite this rationale and good intention, the patient succumbed to a fungal infection, which is a significant complications of allo-BMT.
Currently, there are recommendations that physicians should practice only evidence-based medicine and, consequently, should pursue only those treatment options on which benefits and risks data exist. 42, 43 However, data suggest that only 24% of decisions in hematology-oncology can be supported by a high level of evidence generated from well-designed prospective studies, while 21% of decisions are based on evidence from single-arm prospective studies and 55% of decisions are based on only retrospective or anecdotal evidence. 44 Furthermore, even when results of the studies on the group of patients show high treatment risk, most physicians are willing to recommend a therapy to their individual patients that has a chance of success. 45 Therefore, as illustrated in this case, when data are not available, physicians often define goals of treatment based on their own understanding of the biology of disease and extrapolation of data from one clinical setting to another. 40, 41 Without further treatment, prognosis in chemotherapyrefractory patients with CLL is dismal, 21 and in the absence of curative options for patients with high-risk B-CLL, consideration of MUD BMT is a reasonable alternative. When expected benefits of the treatment exceed its risks, the regret associated with a wrong decision becomes negligible. 26 Perhaps this explains why the patient and his physicians embarked on the course of risky treatment without solid evidence of proven efficacy.
Whatever the course of action pursued by physicians, it must be taken in concert with the patient. In our case, after the patient and physician agreed on the problem, the physician-in-charge presented one or more courses of action to the patient. On multiple occasions, the patient sought the aid of additional consultants. The decisions that were made and the course of medical action were based on the mutual consent of the patient, several consultants, and the physician-in-charge. 46 
